Evidence map›Paper›PMID 37362473›Full record

ArticleCureus2023

Prevalence and Awareness of Diabetic Retinopathy in Diabetic Patients Visiting Tertiary Care Hospitals in Central India.

Shubhangi Setia, Pravin Tidake

Abstract read
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shubhangi SetiaMedicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Pravin TidakeOphthalmology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Diabetes presents a significant and ever-growing burden worldwide, impacting populations across the globe. However, this burden is particularly pronounced in developing economies like India. The rise of diabetes in such regions can largely be attributed to two key factors: the increasing prevalence of overweight/obesity and the adoption of unhealthy lifestyles. Aim and objectives The study's objectives encompassed identifying patients with type 2 diabetes mellitus through the oral glucose tolerance test and the diagnosis of diabetic retinopathy (DR) among them, followed by classification based on the severity of the disease. Furthermore, the study aimed to evaluate the factors associated with DR among the patients, focusing on the duration of diabetes and age group, both of which were deemed highly significant. Methods This cross-sectional study was conducted for two months in 2019 among 40 patients. The tests performed were an oral glucose tolerance test, ocular examination including slit lamp biomicroscopy, and fundus examination. The data were analyzed using the Chi-square test and Student T-test. Results About 42.5% of the patients were positive for diabetic retinopathy, of which 29.41% had mild NPDR, 41.18% had moderate non-proliferative diabetic retinopathy (NPDR), and 29.41% had diabetic maculopathy. No cases of severe NPDR and proliferative diabetic retinopathy (PDR) were found. Conclusion Longer duration of diabetes corresponded to a higher prevalence of diabetic retinopathy. The frequency of diabetic retinopathy was higher in ages above 60 years. Diabetic retinopathy is a concern for patients with a long history of diabetes, high blood sugar levels, and unilateral or bilateral low vision. Thirty percent of the total were newly diagnosed diabetics. Timely screening of patients and intervention can go a long way in reducing morbidity or vision loss.

Indexed as

diabetesetdrshyperglycemianpdrpdrretinopathy

Identifiers

PMID37362473
PMCPMC10287543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.